Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in addressing regulatory issues relating to the field of cancer immunotherapy:
SITC has forged strategic relationships with government and regulatory entities from around the world to address key regulatory issues including formal liaison relationships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute/National Institutes of Health (NCI/NIH).
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
Click here to view a complete listing of these institutions.
There is an urgent need among practicing oncologists and nurses for treatment algorithms that guide management of immunotherapy-related toxicities. Similarly, standardized templates for reporting adverse events in clinical trials are needed in order to facilitate monitoring and reporting of toxicities, an effort which is considered a high priority by the U.S. Food and Drug Administration.
To this end, SITC took the lead to convene a one-day Toxicity Management Workshop on Friday, March 31, 2017, in Washington, D.C. Click here to learn more about this event.
The publication yesterday of the first clinical guidelines by the Society for Immunotherapy of Cancer on management of side effects associated with immunotherapies really felt momentous. We've been talking about these issues for a couple of years ...
It was great seeing old friends again and meeting new ones at the 32 nd Annual Meeting & Pre-Conference Programs in National Harbor! We appreciate all who joined SITC for our most successful Annual Meeting yet and hope you had a great time learning, ...
The cited 2017 case report states " The restoration of the cellular immune response against tumor cells through PD-1 blockade and CRLA-4 blockade have recently been shown to be associated with increased survival in metastatic RCC developed from native ...
This is an interesting subject to me since a few years back we published a study in the American Journal of Transplantation that showed blocking mTOR with a low dose of rapamycin enhanced anti-tumor activity while suppressed allogeneic response in ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org